Corcept Therapeutics Inc. (CORT), which posted strong financial results for the third quarter yesterday, is anticipating a ...

On Monday, Corcept Therapeutics Incorporated (CORT) stock saw a modest uptick, ending the day at $50.06 which represents a slight increase of $2.44 or 5.12% from the prior close of $47.62. The stock ...

Corcept Therapeutics (CORT) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings ...

Shares of Corcept Therapeutics (CORT) have gained 4.8% over the past four weeks to close the last trading session at $47.62, but there could still be a solid upside left in the stock if short-term ...

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, November 5th: ...

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Corcept Therapeutics (CORT – Research Report). The ...

Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a ...

On Tuesday, Corcept Therapeutics Incorporated (CORT) stock saw a decline, ending the day at $48.21 which represents a decrease of $-0.13 or -0.27% from the prior close of $48.34. The stock opened at ...

GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...

Corcept Therapeutics (NASDAQ:CORT) is gearing up to announce its quarterly earnings on Wednesday, 2024-10-30. Here's a quick overview of what investors should know before the release. Analysts are ...